Department of Pediatrics, Mehta Multispeciality Hospitals India Pvt. Ltd, Chennai, Tamil Nadu, India.
Sai Nilayam, New No. 4, Old No. 26, 7th Main Road R.A. Puram, Chennai, Tamil Nadu, 600028, India.
Indian J Pediatr. 2023 Aug;90(8):770-775. doi: 10.1007/s12098-022-04162-8. Epub 2022 Jun 22.
To compare asthma control by Asthma Control Test (ACT)/Childhood Asthma Control Test (cACT) Questionnaire of Global Initiative for Asthma 2017 (GINA-2017) against spirometry in children, 5-18 y of age, with asthma.
A prospective observational study was conducted between July 2017 and March 2019 in pulmonology OPD of a tertiary care center. Children with asthma aged 5-18 y, falling under the inclusion criteria had spirometry and cACT/ACT questionnaire before starting inhaled corticosteroids. After 12 wk, symptom control was reassessed by ACT/cACT and spirometry. Chi-square/Fischer exact test and paired t-test/Mann-Whitney U test used for qualitative and quantitative data, respectively.
ACT/cACT pretreatment score was 12.76 (2.521), and at follow-up the score was 23.94 (1.941) (p < 0.001). Control by GINA increased from 2.04% to 91.84% at follow-up (p < 0.001). Significant improvement in forced expiratory volume in first second (FEV1), forced expiratory volume/forced vital capacity (FEV1/FVC), forced expiratory flow between 25 and 75% of FVC (FEF) and peak expiratory flow rate (PEFR) between pretreatment and follow-up seen were -71.86%, 106.84%, 101.82%, and 97.51% vs. 82.2%, 109.55%, 110.38%, and 107.00%, respectively. Positive correlation between ACT/cACT and FEV1 (r = 0.26, p ≤ 0.05), PEFR (r = 0.30, p ≤ 0.05).
There is a good correlation of symptom control between ACT/cACT and spirometry with significant positive correlation for FEV1, PEFR.
通过比较哮喘控制测试（ACT）/儿童哮喘控制测试（cACT）问卷与全球哮喘倡议 2017 版（GINA-2017）对 5-18 岁哮喘儿童的肺功能的影响，来评估哮喘控制情况。
这是一项前瞻性观察研究，于 2017 年 7 月至 2019 年 3 月在一家三级护理中心的呼吸科门诊进行。年龄在 5-18 岁，符合纳入标准的哮喘儿童在开始吸入皮质激素前进行肺功能和 cACT/ACT 问卷检查。12 周后，通过 ACT/cACT 和肺功能再次评估症状控制情况。使用卡方检验/Fisher 精确检验和配对 t 检验/曼-惠特尼 U 检验分别进行定性和定量数据分析。
ACT/cACT 治疗前评分为 12.76（2.521），随访时评分为 23.94（1.941）（p<0.001）。GINA 控制率从治疗前的 2.04%增加到随访时的 91.84%（p<0.001）。治疗前和随访时，第一秒用力呼气量（FEV1）、用力肺活量（FEV1/FVC）、用力呼出 25%至 75%肺活量时的流量（FEF）和呼气峰值流量（PEFR）分别显著改善-71.86%、106.84%、101.82%和 97.51%、82.2%、109.55%、110.38%和 107.00%。ACT/cACT 与 FEV1（r=0.26，p≤0.05）、PEFR（r=0.30，p≤0.05）呈正相关。
ACT/cACT 与肺功能在症状控制方面具有良好的相关性，FEV1 和 PEFR 呈显著正相关。
